Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

NCT03766490 ·Status: UNKNOWN ·Phase: NA

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

NCT03636685 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

NCT04923906 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

NCT03736837 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC

NCT03769805 ·Status: UNKNOWN ·Phase: NA

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NCT04871997 ·Status: COMPLETED

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

NCT03589950 ·Status: UNKNOWN ·Phase: PHASE2

Phase I Study of the Combination of Anlotinib With Gefitinib

NCT03602027 ·Status: UNKNOWN ·Phase: NA

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

NCT06043973 ·Status: RECRUITING ·Phase: PHASE3

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

NCT03703596 ·Status: UNKNOWN ·Phase: PHASE2

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT02535338 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

NCT02388919 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

NCT03700359 ·Status: UNKNOWN ·Phase: PHASE2

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01101334 ·Status: COMPLETED ·Phase: PHASE2

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

NCT04671303 ·Status: COMPLETED ·Phase: PHASE2

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

NCT03765775 ·Status: UNKNOWN ·Phase: PHASE2

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

NCT04619537 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NCT05778149 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

NCT03728374 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer

NCT04675697 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

NCT04797806 ·Status: UNKNOWN ·Phase: PHASE3

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

NCT04203719 ·Status: UNKNOWN ·Phase: PHASE2

A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)

NCT06982287 ·Status: NOT_YET_RECRUITING

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

NCT05218759 ·Status: NOT_YET_RECRUITING ·Phase: NA

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer

NCT03750916 ·Status: UNKNOWN ·Phase: PHASE2